ReviewJournal of clinical medicine2022
Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 65 citations in OpenAlex.
- LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial.Rheumatology international · 2026Trial
- Cardiovascular Risks in Autoimmune and Inflammatory Diseases.Journal of clinical medicine · 2026Article
- Investigating the Link Between Specific Signaling Molecules (CCL5, CCR5, CXCR4, BMPR2) and Cardiac Health Indicators in Rheumatoid Arthritis Individuals: A Cross-Sectional Study.Health science reports · 2026Article
- Myocardial Injury in Rheumatic Diseases: Immune and Microcirculatory and Molecular Mechanisms of Cardiomyopathies.International journal of molecular sciences · 2026Review
- Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation.ACR open rheumatology · 2026Review
- Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects.Journal of personalized medicine · 2026Review
- Article
- Immunoglobulin G and plasma glycome in early rheumatoid arthritis differ from matched controls and link less fat-free mass to an accelerated aging phenotype: an exploratory study.Arthritis research & therapy · 2026Article
- Renal Vascular Involvement Assessed by Intrarenal Resistive Index in Patients with Rheumatoid Arthritis: Associations with Structural Joint Damage and Cardiovascular Risk.Journal of clinical medicine · 2026Article
- Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification.Circulation · 2026Review
- Neutrophil extracellular traps in rheumatoid arthritis: biomarkers, drivers, and emerging therapeutic targets.Clinical and experimental immunology · 2026Review
- Factors associated with concurrent cardiovascular disease in patients with rheumatoid arthritis and development of machine learning models for comorbidity identification.Frontiers in cardiovascular medicine · 2026Article
- Prevalence and Patterns of Dyslipidemia Among Patients With Rheumatoid Arthritis: A Retrospective Cohort Study.Cureus · 2025Article
- Clonal hematopoiesis of indeterminate potential: a multisystem hub bridging hematopoietic dysfunction with non-hematopoietic diseases.Military Medical Research · 2025Review
- Periodontitis, Dyslipidemia and Rheumatoid Arthritis: An Additive Model of Cardiovascular Risk.Journal of clinical medicine · 2025Article
- Sjogren's Disease and Elevated Cardiovascular Risk: Mechanisms and Treatment.Journal of cardiovascular development and disease · 2025Review
- Arrhythmias in Rheumatoid Arthritis: A Call for a Multidisciplinary Team.Life (Basel, Switzerland) · 2025Review
- Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Healthcare Interventions in the Management of Rheumatic Diseases: A Narrative Analysis of Effectiveness and Emerging Strategies.Healthcare (Basel, Switzerland) · 2025Review
- Effects of Janus Kinase Inhibitors on Cardio-Vascular Risk in Rheumatic Diseases: A Prospective Pilot Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk for developing cardiovascular diseases (CVD) in rheumatoid arthritis (RA) patients is 1.5 times higher compared to the general population. This risk is partly due to the contribution of systemic inflammation in increased atherogenesis, while an increased prevalence of "traditional" cardiovascular risk factors, such as hypertension and dyslipidemia, is also attributed to nearly 50% of the total CVD risk. Most anti-rheumatic medication partly reduces this CVD risk, primarily by reducing inflammation. The increased risk is recognized by most guidelines, which advise consequent screening and multiplying calculated risk scores by 1.5. However, screening in daily clinical practice is poorly done, and RA patients often have undiagnosed and untreated risk factors. In conclusion, even nowadays, RA patients still have an increased risk of developing CVD. Advances in anti-inflammatory treatment partly mitigate this risk, but RA patients need mandatory screening for CV risk factors to turn their CVD risk towards that of the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.